Vancouver-based clinical-stage pharmaceutical company founded in 2021 developing synthetic psilocybin therapy for alcohol use disorder. Its Phase 2b CLARITY trial combines 25 mg synthetic psilocybin with Motivational Enhancement Therapy across sites in Canada and Europe, and had surpassed 90% randomization of its roughly 128-subject study, aiming for regulatory approval in Canada, the EU and UK.
Clairvoyant Therapeutics News 12 articles
- Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant
- Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant
- Psilocybin Clinical Trial Sponsored by Clairvoyant Therapeutics Reaches 90% Randomization
- First Patient Dosed in Europe in Clairvoyant’s Phase 2b Clinical Trial Exploring Psilocybin Therapy as a Treatment for Alcohol Use Disorder
- First Patient Dosed in Clairvoyant’s Phase 2 Clinical Trial Exploring Psilocybin as a Treatment for Alcohol Use Disorder
- Clairvoyant’s Phase 2 Psilocybin Therapy Trial for Alcohol Use Disorder Obtains Regulatory Approval and Initiates 1st Clinical Site in Finland
- Origin Therapeutics’ Portfolio Company, Clairvoyant, Approved for Phase 2 Psilocybin Therapy Trial; First Clinical Site Initiated in Finland
- Clairvoyant’s Phase 2 Psilocybin Therapy Trial for Alcohol Use Disorder Obtains Regulatory Approval and Initiates 1st Clinical Site in Finland
- Clairvoyant Initiates First Site for Phase 2 Psilocybin Therapy Clinical Trial for Alcohol Use Disorder
- Clairvoyant Initiates First Site for Phase 2 Psilocybin Therapy Clinical Trial for Alcohol Use Disorder
- Damian Kettlewell, CEO of Clairvoyant Therapeutics, Sits in the Investor Hotseat – Stream #4
- Clairvoyant Therapeutics Raises More Than $3 Million in Seed Financing, Adds Bench Strength to Senior Leadership Team